Comparative quantitative analysis of BCR-ABL transcripts with the T315I mutant clone by polymerase chain reaction...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Drug resistance is a major challenge in chronic myeloid leukemia (CML) treatment.
• BCR-ABL kinase domain mutations, particularly T315I, confer resistance to targeted therapies.
• Accurate monitoring of mutant-to-wild-type ratios is crucial for assessing treatment efficacy.

Observation:

• A novel polymerase chain reaction (PCR)-Invader assay, termed qPI assay, was developed for quantitative analysis of BCR-ABL transcripts.
• The assay can detect T315I mutant BCR-ABL down to 1% of total transcripts.
• Comparison with direct sequencing and allele-specific oligonucleotide (ASO)-PCR showed high concordance.

Findings:

• The qPI assay demonstrated high sensitivity and specificity in detecting the T315I mutant clone.
• A strong correlation (r2 = 0.951) was observed between the qPI assay and quantitative ASO-PCR for T315I mutant ratios.
• The assay successfully identified T315I mutations in serial samples from CML and Philadelphia-positive acute lymphoblastic leukemia patients.

Implications:

• The qPI assay provides a reliable and sensitive method for evaluating T315I mutant clones in BCR-ABL transcripts.
• This assay can aid in clinical decision-making for CML patients with resistance to tyrosine kinase inhibitors.
• Improved monitoring of drug resistance mutations can lead to more personalized and effective CML treatment strategies.